Page last updated: 2024-11-03

risperidone and Cardiovascular Diseases

risperidone has been researched along with Cardiovascular Diseases in 15 studies

Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.

Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.

Research Excerpts

ExcerptRelevanceReference
"Risperidone and paliperidone palmitate are two antipsychotic drugs well tolerated in the management of schizophrenia and other psychiatric conditions."7.88Risperidone-associated sinus tachycardia potentiated by paliperidone palmitate in a patient with no prior cardiovascular disease: role of risperidone-related autonomic instability. ( Tagne Nouemssi, AB, 2018)
"Data were collected from medical records from January 1992 to December 2003 and included age, gender, race, diagnosis, family history of diabetes, and age at clozapine initiation for clozapine-treated patients with schizophrenia or schizoaffective disorder (DSM-IV criteria)."7.73Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. ( Borba, CP; Cather, C; Copeland, PM; Evins, AE; Freudenreich, O; Goff, DC; Hayden, DL; Henderson, DC; Louie, PM; Nguyen, DD, 2005)
"In March 2004, the UK Committee of Safety of Medicines (CSM) informed clinicians that risperidone and olanzapine should not be used to treat behavioural and psychological symptoms of dementia (BPSD) because of increased risk of strokes with both drugs and increased risk of mortality with olanzapine."7.73Can risperidone and olanzapine in elderly patients with dementia and other mental disorders be discontinued? ( Shah, A, 2006)
"Risperidone and paliperidone palmitate are two antipsychotic drugs well tolerated in the management of schizophrenia and other psychiatric conditions."3.88Risperidone-associated sinus tachycardia potentiated by paliperidone palmitate in a patient with no prior cardiovascular disease: role of risperidone-related autonomic instability. ( Tagne Nouemssi, AB, 2018)
"Following several years of treatment, risperidone discontinuation is associated with a reversal of the excessive weight gain, mediated by a negative energy balance, and a corresponding improvement in cardiometabolic parameters."3.80Cardiometabolic outcomes in children and adolescents following discontinuation of long-term risperidone treatment. ( Burns, TL; Calarge, CA; Nicol, G; Schlechte, JA, 2014)
" The aims of this study were to investigate the antioxidative activity of paraoxonase and assess lipid profile as a cardiovascular risk factor in patients with schizophrenia under long-term clozapine or risperidone treatment."3.80A study of antioxidant activity in patients with schizophrenia taking atypical antipsychotics. ( Atanasiu, V; Delia, C; Gaman, L; Gilca, M; Iosif, L; Piriu, G; Stoian, I, 2014)
"Data were collected from medical records from January 1992 to December 2003 and included age, gender, race, diagnosis, family history of diabetes, and age at clozapine initiation for clozapine-treated patients with schizophrenia or schizoaffective disorder (DSM-IV criteria)."3.73Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. ( Borba, CP; Cather, C; Copeland, PM; Evins, AE; Freudenreich, O; Goff, DC; Hayden, DL; Henderson, DC; Louie, PM; Nguyen, DD, 2005)
"In March 2004, the UK Committee of Safety of Medicines (CSM) informed clinicians that risperidone and olanzapine should not be used to treat behavioural and psychological symptoms of dementia (BPSD) because of increased risk of strokes with both drugs and increased risk of mortality with olanzapine."3.73Can risperidone and olanzapine in elderly patients with dementia and other mental disorders be discontinued? ( Shah, A, 2006)
" Generally, the antipsychotics significantly enhanced NRG1/ErbB signaling with increased expression of NRG1 and phosphorylation of ErbB4 and ErbB2 in the brain and myocardium, except that clozapine partly blocked the cardiac NRG1/ErbB2 activation, which could be associated with its more severe cardiac adverse actions."1.43Effects of prolonged antipsychotic administration on neuregulin-1/ErbB signaling in rat prefrontal cortex and myocardium: implications for the therapeutic action and cardiac adverse effect. ( Cai, H; Dang, R; Guo, Y; Jiang, P; Liang, D; Lv, C; Yang, R, 2016)

Research

Studies (15)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (6.67)18.2507
2000's5 (33.33)29.6817
2010's8 (53.33)24.3611
2020's1 (6.67)2.80

Authors

AuthorsStudies
Hsueh, L1
Iturralde, E1
Slama, NE1
Spalding, SR1
Sterling, SA1
Matera, E1
Margari, L1
Palmieri, VO1
Zagaria, G1
Palumbi, R1
Margari, F1
Tagne Nouemssi, AB1
Gopal, S1
Hough, D1
Karcher, K1
Nuamah, I1
Palumbo, J1
Berlin, JA1
Baseman, A1
Xu, Y1
Kent, J1
Calarge, CA1
Nicol, G1
Schlechte, JA1
Burns, TL1
Gilca, M1
Piriu, G1
Gaman, L1
Delia, C1
Iosif, L1
Atanasiu, V1
Stoian, I1
Pasternak, B1
Svanström, H1
Ranthe, MF1
Melbye, M1
Hviid, A1
Dang, R1
Guo, Y1
Cai, H1
Yang, R1
Liang, D1
Lv, C1
Jiang, P1
Osborn, D1
Marston, L1
Nazareth, I1
King, MB1
Petersen, I1
Walters, K1
Meyer, JM1
Davis, VG1
McEvoy, JP1
Goff, DC2
Nasrallah, HA1
Davis, SM1
Daumit, GL1
Hsiao, J1
Swartz, MS1
Stroup, TS1
Lieberman, JA1
Clark, D1
Skrobot, OA1
Adebiyi, I1
Susce, MT1
de Leon, J1
Blakemore, AF1
Arranz, MJ1
Henderson, DC1
Nguyen, DD1
Copeland, PM1
Hayden, DL1
Borba, CP1
Louie, PM1
Freudenreich, O1
Evins, AE1
Cather, C1
Shah, A1
Zarate, CA1
Baldessarini, RJ1
Siegel, AJ1
Nakamura, A1
McDonald, J1
Muir-Hutchinson, LA1
Cherkerzian, T1
Tohen, M1
Bouchard, RH1
Demers, MF1
Simoneau, I1
Alméras, N1
Villeneuve, J1
Mottard, JP1
Cadrin, C1
Lemieux, I1
Després, JP1

Reviews

1 review available for risperidone and Cardiovascular Diseases

ArticleYear
Risk of cardiovascular morbidity with risperidone or paliperidone treatment: analysis of 64 randomized, double-blind trials.
    Journal of clinical psychopharmacology, 2013, Volume: 33, Issue:2

    Topics: Antipsychotic Agents; Cardiovascular Diseases; Databases, Factual; Drug Labeling; Humans; Incidence;

2013

Trials

1 trial available for risperidone and Cardiovascular Diseases

ArticleYear
Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1.
    Schizophrenia research, 2008, Volume: 103, Issue:1-3

    Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cardiovascular Diseases; Dibenzothiazepines; Female; H

2008

Other Studies

13 other studies available for risperidone and Cardiovascular Diseases

ArticleYear
Cardiometabolic Monitoring and Sociodemographic and Clinical Characteristics of Youths Prescribed Antipsychotic Medications.
    Psychiatric services (Washington, D.C.), 2023, 08-01, Volume: 74, Issue:8

    Topics: Adolescent; Adult; Antipsychotic Agents; Cardiovascular Diseases; Female; Humans; Lipids; Male; Psyc

2023
Risperidone and Cardiometabolic Risk in Children and Adolescents: Clinical and Instrumental Issues.
    Journal of clinical psychopharmacology, 2017, Volume: 37, Issue:3

    Topics: Adolescent; Antipsychotic Agents; Cardiovascular Diseases; Child; Child, Preschool; Female; Follow-U

2017
Risperidone-associated sinus tachycardia potentiated by paliperidone palmitate in a patient with no prior cardiovascular disease: role of risperidone-related autonomic instability.
    BMJ case reports, 2018, Apr-21, Volume: 2018

    Topics: Antipsychotic Agents; Autonomic Nervous System; Cardiovascular Diseases; Diagnosis, Differential; Do

2018
Cardiometabolic outcomes in children and adolescents following discontinuation of long-term risperidone treatment.
    Journal of child and adolescent psychopharmacology, 2014, Volume: 24, Issue:3

    Topics: Adolescent; Cardiovascular Diseases; Child; Female; Follow-Up Studies; Humans; Male; Metabolic Syndr

2014
A study of antioxidant activity in patients with schizophrenia taking atypical antipsychotics.
    Psychopharmacology, 2014, Volume: 231, Issue:24

    Topics: Adult; Antipsychotic Agents; Aryldialkylphosphatase; Cardiovascular Diseases; Clozapine; Female; Hum

2014
Atypical antipsychotics olanzapine, quetiapine, and risperidone and risk of acute major cardiovascular events in young and middle-aged adults: a nationwide register-based cohort study in Denmark.
    CNS drugs, 2014, Volume: 28, Issue:10

    Topics: Administration, Oral; Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Cardiovascular Disea

2014
Effects of prolonged antipsychotic administration on neuregulin-1/ErbB signaling in rat prefrontal cortex and myocardium: implications for the therapeutic action and cardiac adverse effect.
    The Journal of toxicological sciences, 2016, Volume: 41, Issue:2

    Topics: Animals; Antipsychotic Agents; Cardiovascular Diseases; Clozapine; Comorbidity; Genetic Predispositi

2016
Relative risks of cardiovascular disease in people prescribed olanzapine, risperidone and quetiapine.
    Schizophrenia research, 2017, Volume: 183

    Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Cardiovascular Diseases; Cohort Studies; Female;

2017
Apolipoprotein-E gene variants associated with cardiovascular risk factors in antipsychotic recipients.
    European psychiatry : the journal of the Association of European Psychiatrists, 2009, Volume: 24, Issue:7

    Topics: Alleles; Antipsychotic Agents; Apolipoproteins E; Body Mass Index; Cardiovascular Diseases; Diabetes

2009
Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study.
    The Journal of clinical psychiatry, 2005, Volume: 66, Issue:9

    Topics: Adult; Antipsychotic Agents; Black or African American; Cardiovascular Diseases; Cause of Death; Clo

2005
Can risperidone and olanzapine in elderly patients with dementia and other mental disorders be discontinued?
    International journal of geriatric psychiatry, 2006, Volume: 21, Issue:2

    Topics: Administration, Oral; Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Cardiovascular

2006
Risperidone in the elderly: a pharmacoepidemiologic study.
    The Journal of clinical psychiatry, 1997, Volume: 58, Issue:7

    Topics: Age Factors; Aged; Aged, 80 and over; Basal Ganglia Diseases; Cardiovascular Diseases; Comorbidity;

1997
Atypical antipsychotics and cardiovascular risk in schizophrenic patients.
    Journal of clinical psychopharmacology, 2001, Volume: 21, Issue:1

    Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Weight; Cardiovascular Diseases; Cross-Sectional

2001